Patients with BRAF V600E-mutated metastatic colorectal cancer experienced improved responses when treated with Braftovi plus Erbitux and mFOLFOX6.
Three trials presented at ASCO GI 2025 will change practice and improve the treatment of colorectal cancer, according to experts.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback